Second-line CML drug evokes faster response, fewer side effects, pivotal study finds

Saturday, June 5, 2010 - 10:10 in Health & Medicine

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukaemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Centre...

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net